Considering that the RTK inhibitor anlotinib acts as an antiangiogenic drug, we performed angiogenesis-related protein chip screening on KRAS-mutant NSCLC cells treated with the combined strategy. Here, KRAS is linked to non-small cell lung carcinoma.